Search results
1 lut 2011 · For health care–associated MRSA (HA-MRSA) or CA-MRSA pneumonia, IV vancomycin (A-II) or linezolid 600 mg PO/IV twice daily (A-II) or clindamycin 600 mg PO/IV 3 times daily (B-III), if the strain is susceptible, is recommended for 7–21 days, depending on the extent of infection.
5. For empirical coverage of CA-MRSA in outpatients with SSTI, oral antibiotic options include the following: clindamycin (A-II), trimethoprim-sulfamethoxazole (TMP-SMX) (A-II), a tetracycline (doxycycline or minocycline) (A-II), and linezolid (A-II). If coverage for both b-hemolytic streptococci and CA-MRSA is desired, options include the ...
14 lis 2022 · Current guidelines governed by the Infectious Diseases Society of America (IDSA) recommend vancomycin (VAN) or daptomycin (DAP) as first-line agents for treating MRSA bacteremia (MRSA). While both have proved to be efficacious, neither is without limitations [6].
1 lut 2011 · The guidelines discuss the management of a variety of clinical syndromes associated with MRSA disease, including skin and soft tissue infections (SSTI), bacteremia and endocarditis, pneumonia, bone and joint infections, and central nervous system (CNS) infections.
antibiotic susceptibility profiles for CA-MRSA to assist providers in choosing ap-propriate empiric antibiotic therapy. Given the lack of clear-cut guidelines for pharmacologically treating pa-tients who present with CA-MRSA at the time of our study, we con-ducted.
15 sie 2011 · Oral antibiotic options for treating skin and soft-tissue infections in patients with community-associated MRSA include clindamycin, trimethoprim/sulfamethoxazole (TMP/SMX; Bactrim, Septra), a...
2.1.1 MRSA (methicillin-resistant S. aureus) . Strains of S. aureus that are resistant to the isoxazoyl penicillins such as methicillin, oxacillin and flucloxacillin. MRSA are cross-resistant to all currently licensed b-lactam antibiotics. 2.1.2 CA-MRSA (community-associated MRSA) .
